Chromosomal Amplifications and Deletions Characterize Germ Line Tumors

GCTs are histologically heterogeneous and are usually curable with chemotherapy, even after metastasis. Gains of chromosome arm 12p and aneuploidy are nearly universal in GCTs but specific somatic genomic features driving tumor initiation, chemosensitivity, and progression have not been completely characterized.

Investigators at the Dana-Farber Cancer Institute (Boston, MA, USA) used clinical whole-exome and transcriptome sequencing to analyze 59 precursor, primary (testicular and mediastinal), and chemoresistant metastatic human GCTs obtained from 49 patients

They reported in the December 1, 2016, issue of the journal Nature that the primary somatic feature of GCTs was the highly recurrent chromosome arm level amplifications and reciprocal deletions (reciprocal loss of heterozygosity) - variations that were significantly enriched in GCTs compared to 19 other cancer types. These tumors also acquired KRAS mutations during the development from precursor to primary disease, and primary testicular GCTs (TGCTs) expressed uniformly wild type and fully functional p53 tumor suppressor genes.

Detailed examination of samples from germ cell tumors that had developed drug resistance revealed that as the cancers progressed, they showed further increases in chromosomal abnormalities seen in all the tumors.

"The gain and loss of DNA copies shows that the tumors' chromosomes are profoundly deranged," said senior author Dr. Eliezer Van Allen, assistant professor of medicine at the Dana-Farber Cancer Institute, "and represents a hallmark feature we had not noticed before. This abnormality may be linked to the development of germ cell tumors and cause them to be sensitive to chemotherapy, but exactly how it does so remains to be discovered."

Related Links:
Dana-Farber Cancer Institute